Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 8;29(2):924-927.
doi: 10.3390/curroncol29020078.

Report from the Western Canadian Gastrointestinal Consensus Cancer Conference-Management of Total Neoadjuvant Therapy in Rectal Cancer

Howard Lim  1 , Aswin George Abraham  2 , Shahid Ahmed  3 , Shahida Ahmed  4 , Carl J Brown  5 , Bryan Brunet  3 , Janine Davies  1 , Corinne Doll  6 , Dorie-Anna Dueck  3 , Vallerie Gordon  4 , Kimberly Hagel  7 , Pamela Hebbard  4 , Christina A Kim  4 , Duc Le  3 , Richard Lee-Ying  6 , John Paul McGhie  8 , Karen Mulder  2 , Jason Park  5 , Daniel J Renouf  1 , Devin Schellenberg  9 , Ralph P W Wong  4 , Adnan Zaidi  3
Affiliations

Report from the Western Canadian Gastrointestinal Consensus Cancer Conference-Management of Total Neoadjuvant Therapy in Rectal Cancer

Howard Lim et al. Curr Oncol. .

Abstract

An educational session related to the Western Canadian Gastrointestinal Cancer Consensus Conference (WCGCCC) was held virtually on 14 October 2020. The WCGCCC is an interactive multidisciplinary conference attended by health care professionals from across Western Canada (British Columbia, Alberta, Saskatchewan, and Manitoba), who are involved in the care of patients with gastrointestinal cancer. Surgical, medical, and radiation oncologists; pathologists, radiologists, and allied health care professionals participated in presentation and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses current issues in the management of total neoadjuvant therapy in rectal cancer.

Keywords: colorectal cancer; neo-adjuvant chemotherapy; surgery.

PubMed Disclaimer

Conflict of interest statement

Author Janine Davies had clinical trials for BMS, Merck, MedImmune, Astellas Array BioPharma, and is a consultant and a member of the advisory board for AstraZeneca, Eisai, Taiho, and Amgen. Author Christina A. Kim received an unrelated research grant from Celgene Inc, and honorarium from Amgen. Author Howard Lim received honoraria from Merck, BMS, AstraZeneca, Eisai, Taiho, Roche, Amgen, and Bayer for consultant work. Author Richard Lee-Ying had advisory roles for Eisai, Ipsen, AstraZeneca, Roche, and Celgene. Author Karen Mulder has an advisory role for Pfizer Canada, Eisai Inc, Bayer Canada and have received clinical trial funding from Deciphera Pharmaceuticals, BluePrint Medicines, and AstraZeneca. Author Daniel J. Renouf received an unrelated research funding and honoraria from Bayer and Roche, and travel funding and honoraria from Servier, Celgene, Taiho, Ipsen, and AstraZeneca. Author Adnan Zaidi received travel a grant from Roche. The remaining authors declare no conflicts of interest.

References

    1. Bahadoer R.R., A Dijkstra E., van Etten B., Marijnen C.A.M., Putter H., Kranenbarg E.M.-K., Roodvoets A.G.H., Nagtegaal I.D., Beets-Tan R.G.H., Blomqvist L.K., et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): A randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29–42. doi: 10.1016/S1470-2045(20)30555-6. - DOI - PubMed
    1. Thompson H., Kim J.K., Yuval J.B., Verheij F., Patil S., Gollub M.J., Wu A.J.-C., Lee M., Hezel A.F., Marcet J., et al. Survival and organ preservation according to clinical response after total neoadjuvant therapy in locally advanced rectal cancer patients: A secondary analysis from the organ preservation in rectal adenocarcinoma (OPRA) trial. J. Clin. Oncol. 2021;39:3509. doi: 10.1200/JCO.2021.39.15_suppl.3509. - DOI
    1. Conroy T., Bosset J.-F., Etienne P.-L., Rio E., François E., Mesgouez-Nebout N., Vendrely V., Artignan X., Bouché O., Gargot D., et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702–715. doi: 10.1016/S1470-2045(21)00079-6. - DOI - PubMed
    1. Rullier E., Rouanet P., Tuech J.-J., Valverde A., Lelong B., Rivoire M., Faucheron J.-L., Jafari M., Portier G., Meunier B., et al. Organ preservation for rectal cancer (GRECCAR 2): A prospective, randomised, open-label, multicentre, phase 3 trial. Lancet. 2017;390:469–479. doi: 10.1016/S0140-6736(17)31056-5. - DOI - PubMed

Publication types

LinkOut - more resources